Pharma Construct: what changed
Two fiscal years side by side, explained: what moved most in the balance sheet and the result, why the result rose or fell, and where the money went.
Pharma Construct
Largest movements
- Receivables within one year +€233
up €233 (+168.0%), from €139 to €371
- Cash -€71
down €71 (-57.1%), from €125 to €53
mainly Net result for the year (-€983) and Receivables within one year (-€233)
- Other debts +€1,000
up €1,000 (+79.7%), from €1,254 to €2,254
- Profit (loss) carried forward -€983
down €983 (-49.4%), from -€1,991 to -€2,975
- Trade debts +€145
new in 2025: €145
- Gross operating margin +€866
up €866 (+48.9%), from -€1,771 to -€905
From the 2024 result to the 2025 result
Each bar is the change in one income-statement line, as its effect on the result: higher costs pull it down, higher income lifts it.
Cash bridge derived
Derived from the 2024 and 2025 balance sheets and the 2025 result: not a filed cash-flow statement. It shows where the money came from and went.
Every line side by side
| Line | Code | 2024 | 2025 | Change | % |
|---|---|---|---|---|---|
| Total assets | 20/58 | €263 | €425 | +€162 | +61.5% |
| Current assets | 29/58 | €263 | €425 | +€162 | +61.5% |
| Amounts receivable within one year | 40/41 | €139 | €371 | +€233 | +168.0% |
| Other amounts receivable | 41 | €139 | €371 | +€233 | +168.0% |
| Cash at bank and in hand | 54/58 | €125 | €53 | -€71 | -57.1% |
| Total equity and liabilities | 10/49 | €263 | €425 | +€162 | +61.5% |
| Equity | 10/15 | -€991 | -€1,975 | -€983 | -99.2% |
| Contributions | 10/11 | €1,000 | €1,000 | = | 0.0% |
| Profit (loss) carried forward | 14 | -€1,991 | -€2,975 | -€983 | -49.4% |
| Amounts payable | 17/49 | €1,254 | €2,400 | +€1,145 | +91.3% |
| Amounts payable within one year | 42/48 | €1,254 | €2,400 | +€1,145 | +91.3% |
| Trade debts | 44 | - | €145 | +€145 | |
| Suppliers | 440/4 | - | €145 | +€145 | |
| Other amounts payable | 47/48 | €1,254 | €2,254 | +€1,000 | +79.7% |
| Gross operating margin | 9900 | -€1,771 | -€905 | +€866 | +48.9% |
| Operating profit (loss) | 9901 | -€1,771 | -€905 | +€866 | +48.9% |
| Financial charges | 65/66B | €77 | €78 | +€1 | +1.9% |
| Recurring financial charges | 65 | €77 | €78 | +€1 | +1.9% |
| Profit (loss) for the period before taxes | 9903 | -€1,848 | -€983 | +€864 | +46.8% |
| Profit (loss) for the period | 9904 | -€1,848 | -€983 | +€864 | +46.8% |
| Profit (loss) for the period to be appropriated | 9905 | -€1,848 | -€983 | +€864 | +46.8% |
Source: filed annual accounts (NBB), fiscal years ended 31 December 2024 and 31 December 2025. Colour: green is a favourable move for that line, red an unfavourable one. Prepared on 6 October 2026 via checked.be.